Thrombosis in paroxysmal nocturnal hemoglobinuria (Q26853483)

R. J. Kelly

series ordinal

2

1 reference

P. Hillmen

series ordinal

3

1 reference

language of work or name

1 reference

20 June 2013

1 reference

1 reference

121

1 reference

PubMed

issue

25

1 reference

PubMed

page(s)

4985-96; quiz 5105

1 reference

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Lysis and thrombosis: manifestation of the same disease

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Splenic infarction and subsequent splenic rupture in a patient with paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Inhibition of clotting factor XIII activity by nitric oxide

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

2-Butoxyethanol enhances the adherence of red blood cells

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Cerebral arterial thrombosis in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Nitric oxide insufficiency and atherothrombosis

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

A postulated mechanism for heparin's potentiation of C1 inhibitor function

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparin

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Complement activation on platelets: implications for vascular inflammation and thrombosis

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Expression of tissue factor pathway inhibitor by endothelial cells and platelets

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Generation of C5a in the absence of C3: a new complement activation pathway

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Beyond lysis: how complement influences cell fate.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Complement-induced procoagulant alteration of red blood cell membranes with microvesicle formation in paroxysmal nocturnal haemoglobinuria (PNH): implication for thrombogenesis in PNH

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Are patients with paroxysmal nocturnal hemoglobinuria at risk for heparin-induced thrombocytopenia?

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Incidence of diagnosed deep vein thrombosis in the general population: systematic review

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Natural history of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Hemoglobin and the paracrine and endocrine functions of nitric oxide

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Acute mesenteric venous thrombosis: case for nonoperative management

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2-butoxyethanol-induced hemolysis and thrombosis in female rats

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

The platelet function defect of paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Platelet activation leads to activation and propagation of the complement system

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

New insights into paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thrombotic thrombocytopenic purpura during immune reconstitution

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Increased sensitivity to complement of megakaryocyte progenitors in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Activated platelets in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Purpura fulminans in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Management of paroxysmal nocturnal haemoglobinuria: a personal view.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Blood platelets activate the classical pathway of human complement.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Stroke in paroxysmal nocturnal haemoglobinuria: patterns of disease and outcome

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Temporal trends in mortality rates from visceral vein thrombosis in paroxysmal nocturnal haemoglobinuria: An optimistic view

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Heparan sulfate: antithrombotic or not?

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Disseminated thrombosis and bone infarction in female rats following inhalation exposure to 2-butoxyethanol

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Coagulation and innate immune responses: can we view them separately?

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thromboembolic events and haematological diseases: a case of stroke as clinical onset of a paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021

A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2012-09-311381

7 January 2021